Clinical Trial Update: AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial exploring AK104 alone or with chemotherapy as first-line treatment for esophageal squamous cell carcinoma (ESCC). Status and results not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN